SLC5A2 and atrial fibrillation: Emerging evidence also suggests that SGLT2 inhibitors may indirectly modulate epigenetic programs relevant to atrial remodeling, including microRNA expression and chromatin accessibility, further linking metabolic therapy to substrate modification in AF [20].